Mobile Menu
Deals & Transactions

Conyers advises Myovant Sciences Ltd. on their US$218 million IPO

Conyers Dill & Pearman advised Myovant Sciences Ltd. on a highly successful underwritten initial public offering on NYSE of 14,500,000 of its shares, for a total fundraising of US$218 million. Roivant Sciences Ltd., the parent company, remains the majority shareholder. This is the biggest New York IPO in the biotechnology sector so far in 2016 and is the latest biotechnology IPO to use a Bermuda company as the listing vehicle.

Neil Henderson, Robert Alexander and Edward Rance worked on the matter with Cooley LLP acting as US counsel to the issue and Latham & Watkins LLP acting as US counsel to the underwriters.

 


Neil Henderson
Director

Bermuda   +1 441 298 7846



Edward Rance
Associate

Bermuda   +1 441 278 7904


Accolades
_

"They understood the urgency and demanding nature of the deals that we were working on - they were very responsive and commercial, and worked with us to make it happen."
- Chambers Global